|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2010-11-1
|
|
pubmed:abstractText |
To test whether intratumoral gene expression levels and germline polymorphisms predict clinical outcome in metastatic colorectal cancer (mCRC) patients treated with cetuximab and bevacizumab plus irinotecan (CBI) vs. cetuximab and bevacizumab (CB)(BOND2).
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1791-7530
|
|
pubmed:author |
pubmed-author:AzumaMizutomoM,
pubmed-author:BohanesPierreP,
pubmed-author:DanenbergKathleen DKD,
pubmed-author:GergerArminA,
pubmed-author:GordonMichael AMA,
pubmed-author:HollywoodEllenE,
pubmed-author:LenzHeinz-JosefHJ,
pubmed-author:LurjeGeorgG,
pubmed-author:PohlAlexandraA,
pubmed-author:SaltzLeonardL,
pubmed-author:WinderThomasT,
pubmed-author:YanNingN,
pubmed-author:YangDongyunD,
pubmed-author:ZhangWuW
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4209-17
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21036743-Adult,
pubmed-meshheading:21036743-Aged,
pubmed-meshheading:21036743-Aged, 80 and over,
pubmed-meshheading:21036743-Angiogenesis Inhibitors,
pubmed-meshheading:21036743-Antibodies, Monoclonal,
pubmed-meshheading:21036743-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:21036743-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21036743-Camptothecin,
pubmed-meshheading:21036743-Colorectal Neoplasms,
pubmed-meshheading:21036743-Drug Resistance, Neoplasm,
pubmed-meshheading:21036743-Female,
pubmed-meshheading:21036743-Gene Expression,
pubmed-meshheading:21036743-Humans,
pubmed-meshheading:21036743-Male,
pubmed-meshheading:21036743-Middle Aged,
pubmed-meshheading:21036743-Polymorphism, Genetic,
pubmed-meshheading:21036743-Predictive Value of Tests,
pubmed-meshheading:21036743-Survival Rate,
pubmed-meshheading:21036743-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study).
|
|
pubmed:affiliation |
Division of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA 90033, USA.
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|
